BioWorld Today: News to Note - Trevena, Inc.
September 05, 2012 - BioWorld Today
Trevena Inc., of King of Prussia, Pa., said results published in the American Journal of Physiology: Heart and Circulation Physiology, showed that, in mice subject to transient cardiac ischemia, TRV120023, a beta-arrestin-biased angiotensin Type I receptor ligand, stimulated the activation of pro-survival kinase Akt, compared to an unbiased angiotensin receptor blocker, and significantly reduced cardiac apoptosis, TRV120023 is closely related to TRV027, Trevena’s acute heart failure molecule currently in mid-stage clinical trials. In separate news, the company said results of a preclinical pharmacology study published in Circulation: Heart Failure, showed that TRV027, when co-administered with furosemide, reduced cardiac preload and afterload, while preserving the natriuretic and diuretic effects of furosemide and protecting renal function. Those findings indicated TRV027 might work additively or synergistically with loop diuretics like furosemide, which are the current standard of care for treating acute heart failure.